37,317 Shares in Progyny, Inc. $PGNY Acquired by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 37,317 shares of the company’s stock, valued at approximately $803,000.

Several other hedge funds also recently made changes to their positions in the business. USA Financial Formulas bought a new position in shares of Progyny in the 3rd quarter valued at about $100,000. Voya Investment Management LLC raised its stake in Progyny by 9.5% during the third quarter. Voya Investment Management LLC now owns 236,833 shares of the company’s stock worth $5,097,000 after acquiring an additional 20,498 shares in the last quarter. State of Wyoming lifted its stake in shares of Progyny by 368.8% in the 2nd quarter. State of Wyoming now owns 22,793 shares of the company’s stock valued at $501,000 after acquiring an additional 17,931 shares during the last quarter. Nomura Holdings Inc. acquired a new position in shares of Progyny in the second quarter valued at approximately $9,368,000. Finally, Public Sector Pension Investment Board increased its holdings in Progyny by 8.2% in the second quarter. Public Sector Pension Investment Board now owns 254,208 shares of the company’s stock valued at $5,593,000 after purchasing an additional 19,240 shares during the period. 94.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Barclays assumed coverage on shares of Progyny in a research report on Monday, December 8th. They set an “overweight” rating and a $29.00 price target for the company. Wall Street Zen downgraded shares of Progyny from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. KeyCorp raised shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price objective for the company in a research note on Tuesday, November 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $27.50.

Insiders Place Their Bets

In other news, CEO Peter Anevski acquired 79,500 shares of the business’s stock in a transaction on Thursday, November 13th. The shares were acquired at an average price of $24.29 per share, for a total transaction of $1,931,055.00. Following the completion of the transaction, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at approximately $16,523,296.79. The trade was a 13.23% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark S. Livingston sold 21,303 shares of Progyny stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total transaction of $543,226.50. Following the sale, the chief financial officer owned 48,358 shares of the company’s stock, valued at $1,233,129. The trade was a 30.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 22,046 shares of company stock valued at $561,691. 9.40% of the stock is owned by company insiders.

Progyny Stock Performance

PGNY stock opened at $25.80 on Monday. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 40.95, a PEG ratio of 2.03 and a beta of 0.96. The firm has a 50 day moving average price of $23.63 and a 200-day moving average price of $22.71. Progyny, Inc. has a 52-week low of $15.71 and a 52-week high of $27.76.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.06. The firm had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. As a group, sell-side analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.